Topcu Atilla, Saral Sinan, Mercantepe Tolga, Akyildiz Kerimali, Tumkaya Levent, Yilmaz Adnan
Department of Pharmacology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.
Department of Physiology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.
Drug Chem Toxicol. 2023 Jan;46(1):77-87. doi: 10.1080/01480545.2021.2011309. Epub 2021 Dec 13.
Acute kidney injury (AKI) is observed in nearly 60% of patients undergoing cisplatin (CP) therapy. The aim of this study was to reveal the potential effects of apelin-13 (AP-13) in the prevention of CP-induced renal toxicity, together with its antioxidant and anti-inflammatory effect mechanisms. Four experimental groups were established. Group 1, the control group, received 0.9% saline solution alone intraperitoneally (IP). Group 2, the CP group, received CP IP at 5 mg/kg once weekly for four weeks for induction of nephrotoxicity. In Group 3, the CP + Apelin-13 (AP-13) group, AP-13 was prepared at 20 nmol kg/d in sterile pyrogen-free saline before injection every day for four weeks and administered IP. CP was administered IP at 5 mg/kg once weekly for four weeks for induction of nephrotoxicity. In Group 4, the AP-13 group, AP-13 was prepared at 20 nmol kg/d in sterile pyrogen-free 0.9% saline before injection every day for four weeks and administered IP. Thiobarbituric acid reactive substances (TBARS), thiol (-SH), interleukin-1 beta, cleaved caspase-3, 8-hydroxy 2-deoxyguanosine (8-OHdG), and nuclear factor kappa B (NF-κβ/p65) levels were then measured. Increased oxidative stress, inflammation, and apoptosis as a result of CP application activated the cascade. However, AP-13 administration reduced the oxidative stress increased by CIS with the determined antioxidant effect and reduced the damage by increasing total -SH levels. 8-OHdG and NF-κβ/p65, which were up-regulated by triggering oxidative stress and inflammation, were down-regulated through the antioxidant and anti-inflammatory effects of AP-13.
在接受顺铂(CP)治疗的患者中,近60%会出现急性肾损伤(AKI)。本研究旨在揭示apelin-13(AP-13)在预防CP诱导的肾毒性中的潜在作用及其抗氧化和抗炎作用机制。建立了四个实验组。第1组为对照组,仅腹腔注射(IP)0.9%生理盐水溶液。第2组为CP组,每周一次腹腔注射5mg/kg CP,共四周,以诱导肾毒性。第3组为CP + Apelin-13(AP-13)组,在无菌无热原盐水中将AP-13配制成20nmol/kg/d,每天注射前配制四周,然后腹腔注射。每周一次腹腔注射5mg/kg CP,共四周,以诱导肾毒性。第4组为AP-13组,在无菌无热原的0.9%盐水中将AP-13配制成20nmol/kg/d,每天注射前配制四周,然后腹腔注射。然后测量硫代巴比妥酸反应物质(TBARS)、巯基(-SH)、白细胞介素-1β、裂解的半胱天冬酶-3、8-羟基-2-脱氧鸟苷(8-OHdG)和核因子κB(NF-κβ/p65)水平。CP应用导致氧化应激、炎症和细胞凋亡增加,激活了级联反应。然而,AP-13给药通过确定的抗氧化作用降低了CIS增加的氧化应激,并通过增加总-SH水平减少了损伤。通过触发氧化应激和炎症而上调的8-OHdG和NF-κβ/p65,通过AP-13的抗氧化和抗炎作用而下调。